OTCMKTS:BCTXF BriaCell Therapeutics (BCTXF) Stock Price, News & Analysis $0.70 +0.04 (+6.57%) As of 08/22/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About BriaCell Therapeutics Stock (OTCMKTS:BCTXF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BriaCell Therapeutics alerts:Sign Up Key Stats Today's Range$0.63▼$0.7050-Day Range$0.63▼$3.1652-Week Range$3.25▼$17.50Volume808,277 shsAverage Volume1,859 shsMarket Capitalization$538.78 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada. Read More Receive BCTXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCTXF Stock News HeadlinesBriaCell Announces Share Consolidation to Maintain Nasdaq ComplianceAugust 9, 2025 | theglobeandmail.comBriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast CancerJuly 15, 2025 | finance.yahoo.com“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.August 26 at 2:00 AM | InvestorPlace (Ad)BriaCell Therapeutics Corp.: BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast CancerJuly 8, 2025 | finanznachrichten.deBriaCell Therapeutics Corp.: BriaCell Bria-OTS Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint InhibitorMay 27, 2025 | finanznachrichten.deBriaCell Stock Dips After-Hours On Pricing $13.8M Public Offering, But Retail's Busy Cheering Clinical MilestoneApril 24, 2025 | msn.comBriaCell confirms 100% resolution of lung metastasis with Bria-OTSApril 24, 2025 | markets.businessinsider.comBriaCell reports survival boost in breast cancer studyApril 18, 2025 | uk.investing.comSee More Headlines BCTXF Stock Analysis - Frequently Asked Questions How have BCTXF shares performed this year? BriaCell Therapeutics' stock was trading at $0.5558 on January 1st, 2025. Since then, BCTXF stock has increased by 25.6% and is now trading at $0.6979. How do I buy shares of BriaCell Therapeutics? Shares of BCTXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:BCTXF CIKN/A Webwww.briacell.com Phone(604) 921-1810FaxN/AEmployees8Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.68 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-786.77% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.55) per share Price / Book-0.15Miscellaneous Outstanding Shares772,000Free FloatN/AMarket Cap$538.78 thousand OptionableNot Optionable Beta1.09 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (OTCMKTS:BCTXF) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s national nightmare is hereWhile the headlines focus on global conflicts, there’s a very different crisis brewing at home. Washington has...Porter & Company | SponsoredIt’s game over for Central BanksCentral banks are losing control. Inflation isn’t fixed, debt is exploding, and stocks have never looked more ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BriaCell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access